Mission

Sibylla aims to revolutionize the Targeted Protein Degradation (TPD) field by unveiling a novel class of folding interfering degraders.

Complexity needs fast adapting innovation. Innovation today must adapt to a world where continuous discoveries set increasingly challenging goals. Innovation requires a change of mindset, where one should not be afraid to walk off the pathway.

At Sibylla, we believe that innovation and fresh perspective must never stop. We are innovating the complex ecosystem of drug discovery through a multidisciplinary and bold team of enthusiastic scientists. Our competencies range from computer science to medicinal chemistry, from computational biophysics to molecular biology. These are not keywords in a broader environment. Indeed, they are the building bricks of a fast-changing environment that builds new deep tech possibilities out of the arising technologies.

Having validated our proprietary platform, we continue to scale our pipeline. The medical world needs a more significant number of druggable targets and people who believe that things can change. At Sibylla, we work in this direction

Vision

Sibylla’s vision is to treat cancer indications with a high unmet need.

We have the ambition of saving human lives and improving the quality of life of the people they love. The life-lasting engagement of our academic founders remains developing therapeutics which have the potential to make a meaningful impact on the lives of patients.

The objective that drives everybody at Sibylla is precisely the same: to work hard and passionately because one day, a diagnosis of severe disease could be followed by the indication of life-saving therapy. We aim at relieving both the patients with their families and friends and the medical staff from the burden of cancer.